BRAF and chordoma: Of these, 27 compounds selectively targeted chordoma cells but not human dermal fibroblasts (Table 1), and 21 of these 27 compounds (78%) represented EGFR/ERBB family inhibitors (Table 1, Figure 2), of which five also represented BRAF inhibitors.